Skip to content
Triangle logo TriangleGet started
← Chronic Lymphocytic Leukemia

HEALTH PROFESSIONAL · SOURCE READING

Treatment Options for Symptomatic or Progressive Chronic Lymphocytic Leukemia (CLL)

Source: Chronic Lymphocytic Leukemia Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: April 25, 2025 · Captured 2026-09-09.

Selected source text with whitespace normalised. This Triangle page is not an NCI PDQ summary.

Context: Treatment of Symptomatic or Progressive Chronic Lymphocytic Leukemia

The following regimens are considered first-line treatment approaches for patients with CLL who are experiencing symptomatic progression:

Bruton tyrosine kinase (BTK) inhibitors (acalabrutinib, zanubrutinib, or ibrutinib).

Source links and citations

Venetoclax with initial use of obinutuzumab or rituximab.

Source links and citations

Bendamustine and rituximab (BR).

Source links and citations

Fludarabine, cyclophosphamide, and rituximab (FCR).

Source links and citations

BTK inhibitor (ibrutinib or acalabrutinib) plus venetoclax.

Source links and citations

R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) (only if Richter syndrome with histological progression is suspected clinically).

Several large prospective clinical trials have compared these approaches. A chemotherapy-free approach for first-line therapy is usually preferred for most patients, but it is mandatory for patients with del(17p) or TP53-altered disease.[1-5]

Source links and citations

Continue within this section

BTK inhibitors →Venetoclax with initial use of obinutuzumab and rituximab →Bendamustine and rituximab →Fludarabine, cyclophosphamide, and rituximab (FCR) →BTK inhibitor plus venetoclax →

Publication references

Read the original reference and check its publication notices.

Preserved source evidence · Not medical advice